PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAlemtuzumab
Campath , Mabcampath(alemtuzumab)
Campath, Lemtrada (alemtuzumab) is an antibody pharmaceutical. Alemtuzumab was first approved as Campath on 2001-05-07. It is used to treat b-cell chronic lymphocytic leukemia in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia and multiple sclerosis. The pharmaceutical is active against CAMPATH-1 antigen.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
nervous system diseasesD009422
hemic and lymphatic diseasesD006425
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Campath (discontinued: Campath)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Alemtuzumab
Tradename
Proper name
Company
Number
Date
Products
LemtradaalemtuzumabSanofiN-103948 RX2014-11-14
1 products
Campath alemtuzumabSanofiN-103948 RX2004-10-12
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
campathBiologic Licensing Application2024-12-11
lemtradaBiologic Licensing Application2024-05-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
b-cell chronic lymphocytic leukemia—D015451C91.1
Agency Specific
FDA
EMA
Expiration
Code
alemtuzumab, Campath , Genzyme Corporation
2108-05-07Orphan excl.
alemtuzumab, Lemtrada, Genzyme Corporation
2108-05-07Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA34: Alemtuzumab
HCPCS
Code
Description
J0202
Injection, alemtuzumab, 1 mg
Clinical
Clinical Trials
389 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G352266520
SclerosisD012598——2265418
Relapsing-remitting multiple sclerosisD020529EFO_0003929——144110
Nerve degenerationD009410—————1—1
Chronic inflammatory demyelinating polyradiculoneuropathyD020277EFO_1000868G61.81———1—1
PolyradiculoneuropathyD011129EFO_1001116————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C95472—314
Lymphoid leukemiaD007945—C91352—211
B-cell chronic lymphocytic leukemiaD015451—C91.1242—210
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.944———5
Non-hodgkin lymphomaD008228—C85.932———3
Myelodysplastic syndromesD009190—D4611———1
Myeloid leukemia acuteD015470—C92.011———1
Myeloid leukemiaD007951—C9211———1
PreleukemiaD011289——11———1
Prolymphocytic leukemia t-cellD015461—C91.6—1———1
Prolymphocytic leukemiaD015463———1———1
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.011———1
T-cell lymphomaD016399——11———1
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Large b-cell lymphoma diffuseD016403—C83.31————1
B-cell lymphomaD016393——1————1
Chronic progressive multiple sclerosisD020528EFO_0003840—1————1
Graft vs host diseaseD006086—D89.811————1
Hematologic neoplasmsD019337——1————1
NeoplasmsD009369—C801————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell leukemiaD015448——————11
Covid-19D000086382—U07.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAlemtuzumab
INNalemtuzumab
Description
Immunoglobulin G 1 (human-rat monodonal CAMPATH-1H 71-chain anti-human antigen CD52), disulfide with human-rat monoclonal CAMPATH-1H light chain, dimer
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>1CE1:H|PROTEIN (CAMPATH-1H:HEAVY CHAIN) QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQ FSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE >1CE1:L|PROTEIN (CAMPATH-1H:LIGHT CHAIN) DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQP EDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
Identifiers
PDB1BEY, 1BFO, 1CE1, 6OBD
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201587
ChEBI ID—
PubChem CID—
DrugBankDB00087
UNII ID3A189DH42V (ChemIDplus, GSRS)
Target
Agency Approved
CD52
CD52
Organism
Homo sapiens
Gene name
CD52
Gene synonyms
CDW52, HE5
NCBI Gene ID
1043
Protein name
CAMPATH-1 antigen
Protein synonyms
Cambridge pathology 1 antigen, CD52, CD52 antigen (CAMPATH-1 antigen), CDw52, CDW52 antigen (CAMPATH-1 antigen), Epididymal secretory protein E5, epididymis secretory sperm binding protein Li 171mP, He5, HEL-S-171mP, Human epididymis-specific protein 5
Uniprot ID
Q9BW46
Mouse ortholog
Cd52 (23833)
CAMPATH-1 antigen (Q64389)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 14,065 documents
View more details
Safety
Black-box Warning
Black-box warning for: Campath, Lemtrada
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
18,674 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use